Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 3.7% Higher – Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares shot up 3.7% during trading on Tuesday . The stock traded as high as $7.20 and last traded at $7.02. 4,972,649 shares changed hands during trading, a decline of 28% from the average session volume of 6,902,442 shares. The stock had previously closed at $6.77.

Analyst Ratings Changes

RXRX has been the subject of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Leerink Partners reduced their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group lowered their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $9.25.

Recursion Pharmaceuticals Price Performance

The stock’s fifty day simple moving average is $6.81 and its 200-day simple moving average is $7.11. The company has a market capitalization of $1.95 billion, a P/E ratio of -4.44 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the previous year, the firm posted ($0.43) EPS. The business’s revenue for the quarter was up 147.6% compared to the same quarter last year. On average, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the sale, the chief financial officer now directly owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Christopher Gibson sold 20,000 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total transaction of $123,200.00. Following the completion of the transaction, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at $4,697,960.96. This trade represents a 2.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 90,341 shares of company stock valued at $611,490 in the last quarter. Corporate insiders own 15.75% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its holdings in shares of Recursion Pharmaceuticals by 6.1% during the third quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company’s stock valued at $7,751,000 after acquiring an additional 67,464 shares during the period. Franklin Resources Inc. increased its position in shares of Recursion Pharmaceuticals by 58.9% during the 3rd quarter. Franklin Resources Inc. now owns 18,963 shares of the company’s stock worth $127,000 after purchasing an additional 7,027 shares in the last quarter. Sanctuary Advisors LLC bought a new position in Recursion Pharmaceuticals during the 3rd quarter valued at about $89,000. Geode Capital Management LLC grew its stake in Recursion Pharmaceuticals by 13.7% during the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after buying an additional 656,003 shares during the last quarter. Finally, Barclays PLC increased its holdings in shares of Recursion Pharmaceuticals by 53.9% during the third quarter. Barclays PLC now owns 697,432 shares of the company’s stock worth $4,596,000 after buying an additional 244,278 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.